Biotech

Takeda's Dengue Vaccine Gets WHO Approval, Eligible for UN Procurement
No Wegovy Shortage in Denmark Amid High Demand, Novo Nordisk Confirms
Eli Lilly Strikes Deal To Combat Counterfeit Diabetes And Weight Loss Drugs Mounjaro And Zepbound
No Wegovy Shortage in Denmark Amid High Demand, Novo Nordisk Confirms
Eli Lilly Strikes Deal To Combat Counterfeit Diabetes And Weight Loss Drugs Mounjaro And Zepbound
DNA Medicine Focused INOVIO Pharma Efficiencies Implemented By Leadership Will Help De-Risk Its Platform Technology: Analyst
FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months

Biotech Recent News

FDA Declines To Approve Expanded Use of Dynavax's Hepatitis B Vaccine In Hemodialysis Patients
Latest regulatory update from Dynavax on HEPLISAV-B vaccine regimen for adults on hemodialysis, with FDA's Complete Response Letter.
Novo Nordisk's Wegovy Delivers: Long-Term Study Shows Sustained Weight Loss As Drugmaker Tries To Woo Insurers And Governments
The data could potentially bolster Novo's case for Wegovy as it attempts to convince insurers and governments to cover the cost of the drug.
Coca-Cola, PepsiCo And Nestlé Are Top Plastic Polluters: Is Hemp The Answer To Nanoplastics In The Oceans??
According to a new study published in Science Advances, fifty-six brands led by Coca-Cola (NYSE: KO), PepsiCo (NASDAQ: PEP), and Nestlé (SWX: NESN) are responsible for more
Vaxart Stock Climbs After Blockbuster Q1 Revenue
Vaxart reported quarterly losses of 14 cents per share, inline with the analyst consensus estimate. Quarterly sales clocked in at $2.181 million, beating the analyst consensus estimate of $800,000 by 172.63% and representing a 223.11% increase over sales of $675,000 from the same period last year.
Johnson & Johnson's Subsidiary Discontinues Some Megadyne Electrodes For Pediatric Use
Johnson & Johnson's Megadyne Mega Soft Pediatric Patient Return Electrodes recalled due to patient burns. FDA's Class I recall impacts 21,200 devices.
Why Is Inventiva's Stock Trading Higher on Monday?
Inventiva's Lanifibranor improves cardiometabolic health in MASH/NASH patients. It lowers fasting glucose, reduces cardiovascular risk, and increases adiponectin levels. Weight gain correlates with health improvement.
Novo Nordisk's Hemophilia Candidate Can Prevent Bleeding Episodes Effectively, Regardless Of Dosing Frequency
Novo Nordisk's Phase 3a trial demonstrates a significant reduction in bleeding episodes with Mim8 treatment for hemophilia A patients. Superior efficacy and safety profile revealed.
Why Is Small-Cap Alzheimer's-Focused AC Immune Stock Trading Higher On Monday?
Unlocking hope for Alzheimer's with ACI-24.060. Takeda's agreement with AC Immune targets toxic forms of Abeta, potentially slowing disease progression.
Valneva Seeks Expanded Use For Its Chikungunya Vaccine In Adolescents With Encouraging Phase 3 Data
Valneva released positive Phase 3 data for its single-shot chikungunya virus vaccine in adolescents. The vaccine is also expected to be approved for use in Brazil.
Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma Treatment
Merck halts vibostolimab and pembrolizumab coformulation arm in KeyVibe-010 Phase 3 trial for high-risk melanoma due to higher discontinuation rates and immune-related adverse events.
MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths'
Despite MacroGenics' clinical activity, unexpected adverse events raise concerns. Analysts adjust ratings and price targets.
From Hype To Reality, AI Reshapes Pharmaceutical Industry Across Drug Discovery To Marketing - Stocks To Watch
Unlock the potential of AI in pharmaceuticals. With AI's help, the pharma industry could see $60B-$110B in annual economic value. Dive into the future of drug discovery and clinical development with leading players like Google, Nvidia, and Microsoft.
MacroGenics Shares Tumble After Reporting Adverse Events, Multiple Deaths In Cancer Drug Trial
Latest interim data from TAMARACK Phase 2 study by MacroGenics unveils insights into vobramitamab duocarmazine targeting B7-H3 in metastatic prostate cancer. Despite responses, notable safety concerns reported.

Explore Benzinga's Financial Tools

Find Stocks Tailored to Your Trading Interests
Find Stocks Tailored to Your Trading Interests
Benzinga Pro offers a real-time newsfeed as headlines break on earnings releases, analyst ratings, rumors, the biggest movers, and many more actionable alerts.

Compare Benzinga's Favorite Stock Brokers

Claim Exclusive Offers

Compare Benzinga's Favorite Cryptocurrency Brokers

Claim Exclusive Offers